Blueprint Medicines (BPMC) Tops Q2 EPS by 49c ; Offers Guidance

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.80), $0.49 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $138.2 million versus the consensus estimate of $103.57 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $435-450 million, versus the consensus of $434.9 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• BNP Paribas Exane Upgrades Novonesis A/S (NSISB:DC) to Neutral
• Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview